Aabo K, Roed H, Vindeløv L L, Spang-Thomsen M
University Institute of Pathological Anatomy, University of Copenhagen, Denmark.
Cancer Res. 1994 Jun 15;54(12):3295-9.
In order to address the question of the influence of a primarily chemoresistant tumor cell subpopulation on the progression of a heterogeneous tumor after cytotoxic therapy, in vitro established human small cell lung cancer cell lines of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive (592) and a resistant (NYH) tumor were used to produce mixed solid tumors in nude mice. Mixtures of 592/NYH (9:1 and 1:1) were inoculated s.c. After 3-4 weeks of tumor growth, the mice were stratified according to tumor size and randomized to treatment with BCNU 40 mg/kg i.p. (10% of lethal dose) or no treatment. Tumor growth curves were used to calculate the effect of the treatment, and changes in the relative proportions of 592 and NYH in the mixed tumors were monitored by flow cytometric DNA analysis by which the two cell lines were distinguishable due to differences in DNA content. A significant response was demonstrated in the 9:1 mixed tumors in which only 592 cells were detectable at the start of the treatment. The response was short and less pronounced compared with tumors containing only 592. In the regrowing tumors after treatment, only NYH was detected. In untreated 9:1 mixed control tumors, only 592 cells were detectable throughout the entire observation period. It is substantiated that the 592 cells were able to inhibit the growth of the NYH cells completely when grown together in 9:1 mixed tumors. This was not the case in the 1:1 mixed tumors. The 1:1 mixed tumors did not respond to BCNU, although 592 was eradicated. These results indicate that resistant and undetectable (dominated) subpopulations in heterogeneous tumors may be responsible for relapse and that the fractional size and the growth characteristics of the resistant subpopulation may determine the magnitude of the clinical response to cytotoxic treatment.
为了探讨主要化学抗性肿瘤细胞亚群对细胞毒性治疗后异质性肿瘤进展的影响,使用体外建立的对1,3 - 双(2 - 氯乙基)-1 - 亚硝基脲(BCNU)敏感(592)和耐药(NYH)的人小细胞肺癌细胞系在裸鼠中产生混合实体瘤。接种592/NYH的混合物(9:1和1:1)皮下注射。肿瘤生长3 - 4周后,根据肿瘤大小对小鼠进行分层,并随机分为接受40 mg/kg腹腔注射BCNU(致死剂量的10%)治疗或不治疗。用肿瘤生长曲线计算治疗效果,并通过流式细胞术DNA分析监测混合肿瘤中592和NYH相对比例的变化,由于DNA含量的差异,这两种细胞系是可区分的。在9:1的混合肿瘤中显示出显著反应,在治疗开始时仅可检测到592细胞。与仅含592的肿瘤相比,该反应短暂且不太明显。在治疗后复发的肿瘤中,仅检测到NYH。在未经治疗的9:1混合对照肿瘤中,在整个观察期内仅可检测到592细胞。证实当在9:1的混合肿瘤中共同生长时,592细胞能够完全抑制NYH细胞的生长。在1:1的混合肿瘤中情况并非如此。1:1的混合肿瘤对BCNU无反应,尽管592被根除。这些结果表明,异质性肿瘤中的耐药和不可检测(占主导)亚群可能是复发的原因,并且耐药亚群的分数大小和生长特性可能决定细胞毒性治疗临床反应的程度。